Volume 3 Supplement 1

Abstracts of the Breast Cancer Immunotherapy Symposium (BRECIS): Sidra Symposia Series

Open Access

Carbon nanomaterials as contrast agents for breast cancer diagnosis and therapy

  • Sara Dolci1,
  • Valentina Domenici1,
  • Gianpaolo Vidili2,
  • Elisabetta Avitabile2,
  • Marco Orecchioni2,
  • Alberto Bianco3 and
  • Lucia Delogu2
Journal for ImmunoTherapy of Cancer20153(Suppl 1):P5

https://doi.org/10.1186/2051-1426-3-S1-P5

Published: 14 August 2015

Nanotechnology is the promise to fight breast cancer (BC) more specifically and effectively [1]. In this context carbon nanomaterials (CNs) have attracted the scientific community and the public interest [2]. Common modalities for BC diagnosis are ultrasonography (US) and magnetic resonance imaging (MRI). US is the most useful modality in the evaluation of palpable BC masses that are mammographically occult in women younger than 30’s. Here we show CNs as highly and long lasting echogenic materials. Experiments on swine models confirmed that CNs are clearly visible under US and didn’t exert toxicity. In the current market dual-imaging agents are missed; here we also demonstrate the immune-compatibility and high echogenic properties in water and in whole blood of cysteine functionalized super paramagnetic nanoparticles (CY-SPION), well-known MRI agents [3]. Thanks to these findings, and the ability to load CNs to many moieties [46], we propose dual-contrast agents, CNs-CY-SPION conjugates, to improve BC diagnosis. Future perspectives is to conjugate CN-SPION to targeted drugs against BC. In summary, we lay the foundations for novel contrast agents, for therapy and multimodal diagnosis of BC, combining high imaging performances with unique potential therapeutic applications, such as specific targeting capabilities, drug delivery, immunotherapy and hyperthermia.

Authors’ Affiliations

(1)
University of Pisa
(2)
University of Sassari
(3)
CNRS, Institut de Biologie Moléculaire et Cellulaire, Laboratoire d’Immunologie et Chimie Thérapeutiques

References

  1. Avitabile E, Bedognetti D, Sgarella F, Delogu LG: Nanotechnology fight for breast cancer. (under preparation)Google Scholar
  2. Sechi G, Bedognetti D, Sgarrella F, Van Eperen, L, Marincola FM, Bianco A, Delogu LG: The perception of nanotechnology and nanomedicine: a worldwide social media study. Nanomedicine. 2014, 9 (10): 1475-86. 10.2217/nnm.14.78.View ArticlePubMedGoogle Scholar
  3. Dolci A, Ierardic V, Gradi A, Jagli Z, Remskard M, Apihd T, Cifellia M, Pampalonia G, Veracinia CA, Domenici V: Precursors of Magnetic Resonance Imaging Contrast Agents Based on Cystine-coated Iron-oxide Nanoparticles. Current Physical Chemistry. 2013, 3 (4): 493-500. 10.2174/18779468113036660009.View ArticleGoogle Scholar
  4. Delogu LG, Magrini A, Bergamaschi A, Rosato N, Dawson MI, Bottini N: Conjugation of antisense oligonucleotides to PEGylated carbon nanotubes enables efficient knockdown of PTPN22 in T lymphocytes. Bioconjug Chem. 2009, 18 (20): 427-431. 10.1021/bc800540j.View ArticleGoogle Scholar
  5. Delogu LG, Venturelli E, Manetti R, Pinna GA, Carru C, Madeddu R, Murgia L, Sgarrella F, Dumortier H, Bianco A: Ex vivo impact of functionalized carbon nanotubes on human immune cells. Nanomedicine (Lond). 2012, 7 (2): 231-243. 10.2217/nnm.11.101.View ArticleGoogle Scholar
  6. Modugno G, Ménard-Moyon C, Prato M, Bianco A: Carbon nanomaterials combined with metal nanoparticles for theranostic applications. Br J Pharmacol. 2015, 172 (4): 975-91. 10.1111/bph.12984.View ArticlePubMedGoogle Scholar

Copyright

© Dolci et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement